CDK4/6 Inhibitors Adverse Reaction Grading and Dosing Chart
This resource is intended to guide providers caring for patients that have HR+ HER2- metastatic breast cancer and are receiving CDK4/6 inhibitors for their treatment and are experiencing adverse reactions that indicate a need for dose adjustment. Reference these easy to interpret dosing guides.